| Identification | More | [Name]
beta-Amyrin | [CAS]
559-70-6 | [Synonyms]
12-OLEANEN-3-BETA-OL
12-OLEANIN-3-BETA-OL
(3BETA)-OLEAN-12-EN-3-OL
AMYRIN, B-
B-AMYRIN
BETA-AMYRIN
OLEAN-12-EN-3BETA-OL
OLEAN-12-EN-3B-OL
beta-Amyrenol
Olean-12-en-3-ol
Olean-12-en-3-ol, (3beta)-
beta-AMYRIN hplc
B-AMYRIN WITH HPLC
(3S,4aR,6aR,6bS,8aR,12aR,14aR,14bR)-4,4,6a,6b,8a,11,11,14b-Octamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-ol
3b-Hydroxyolean-12-ene
b-Amyrenol
Olean-12-en-3-ol, (3b)-
5α-Olean-12-en-3β-ol
β-Amyrine | [EINECS(EC#)]
209-204-6 | [Molecular Formula]
C30H50O | [MDL Number]
MFCD00017381 | [Molecular Weight]
426.72 | [MOL File]
559-70-6.mol |
| Chemical Properties | Back Directory | [Melting point ]
187-190°C | [alpha ]
D19 +99.8° (c = 1.3 in benzene) | [Boiling point ]
bp0.8 260° | [density ]
0.9600 (rough estimate) | [refractive index ]
1.4910 (estimate) | [storage temp. ]
Refrigerator | [solubility ]
Chloroform (Slightly), Methanol (Slightly, Heated) | [form ]
Solid | [pka]
15.18±0.70(Predicted) | [color ]
White to Off-White | [optical activity]
+9120 (c 1.23, CHCl3) | [BRN ]
2063468 | [InChIKey]
JFSHUTJDVKUMTJ-QHPUVITPSA-N | [LogP]
10.481 (est) | [CAS DataBase Reference]
559-70-6(CAS DataBase Reference) | [NIST Chemistry Reference]
«BETA»-amyrin(559-70-6) |
| Safety Data | Back Directory | [Hazard Codes ]
Xi | [Risk Statements ]
R22:Harmful if swallowed. | [Safety Statements ]
S22:Do not breathe dust .
S45:In case of accident or if you feel unwell, seek medical advice immediately (show label where possible) . | [WGK Germany ]
3
| [F ]
10-23 |
| Hazard Information | Back Directory | [Uses]
nociceptive | [Definition]
ChEBI: A pentacyclic triterpenoid that is oleanane substituted at the 3beta-position by a hydroxy group and containing a double bond between positions 12 and 13. It is one of the most commonly occurring triterpenoids in higher plants. | [Biological Activity]
Triterpene th at has broad-spectrum analgesic properties for which the underlying mechanism is poorly understood. | [in vivo]
β-Amyrin (4 mg/kg, p.o., daily, 5 days) ameliorates object recognition memory deficit and neurogenesis impairments in the hippocampus of Aβ-induced AD model mice[1].
β-Amyrin (20-100 μg, i.p.) inhibits carrageenan-induced paw edema of rats[2].
β-Amyrin (20-80 mg/kg, i.g., daily, 5 days) has a potent efficacy in protecting against BLM-induced mice pulmonary fibrosis via suppressing inflammatory response and oxidative stress[3].
Pharmacokinetic parameters of β-Amyrin in rats | β-Amyrin standard IV (group 3) | β-Amyrin standard
oral dose (group 2) | | | Dose (mg kg?1) | 1 | 3 | 300 (equivalent of 3mg kg?1 β-amyrin) | | V (ml kg?1) | 1317 | | | | AUC0→24 h (min μg ml?1) | 411 | 10.6 | 47.3 | | Cl (ml min?1 kg?1) | 2.04 | | | | t1/2λZ (h) | 10.2 | 10.3 | 8.3 | | MRT0→24 h (h) (h) | 8 | 8.5 | 8.7 | | Cmax (ng ml?1) (h) (h) | | 18.7 | 75 | | tmax (h) | - | 3 (n = 2) or 5 (n = 1) | 3 (n = 3) or 5 (n = 1) | | F (%) | | 0.86 | 3.83 |
| Animal Model: | Male CD-1 mice, 26-28 g, 6 weeks old. 5 μL of Aβ was acutely injected into the left lateral ventricle by hand[1]. | | Dosage: | 4 mg/kg | | Administration: | p.o., daily, 5 days | | Result: | Increased number of transitions between the light and dark compartments.
Increased the total exploration time on the light compartment of the apparatus and the time spent in
open arms.
Ameliorated the reduction of neurogenesis.
|
| Animal Model: | Adult male rats of Sprague–Dawley strain, weighing 150-180 g. Carrageenan induces
edema in the hind paw of the rat[2].
| | Dosage: | 20, 50, 100 μg/kg | | Administration: | i.p. | | Result: | Significant decreased edema by in a dose dependent manner.
|
| Animal Model: | Adult male rats of Sprague–Dawley strain, weighing 150-180 g. Carrageenan induces
Use Bleomycin (BLM) (HY-108345), 5mg/kg, one-time intratracheally injection, in 50μL saline per mouse to induce the marine model of pulmonary fibrosis[3]. | | Dosage: | 20, 40, 80 mg/kg | | Administration: | i.g., daily, 5 days | | Result: | Promoted the values of SO2 and PO2 and inhibited the value of PCO2.
Significantly improved inflammatory cell infiltration, the thickened alveolar septum and the lesion collapses of the alveoli and formation of flaky lung tissue.
|
| [target]
GABA Receptor | P450 (e.g. CYP17) | cAMP | PKC | PKA | PGE | TNF-α | Antifection | [storage]
Store at -20°C |
|
|